Diagnos Inc's stock has experienced a slight decline this week despite a notable surge over the past month, reflecting ongoing developments in the healthcare technology sector.
Diagnos Inc (ADK.V) has seen its stock price fluctuate recently, with a 1-day change of 0.00% and a weekly decrease of 5.00%. However, the stock remains up significantly over the past month, showing a 43.94% increase. The company's recent achievements in securing medical device licenses have positioned it for growth in the healthcare market, though investor sentiment appears mixed as reflected in the stock's performance.
Advertisement
Diagnos Inc
ADK.V
ADK.V
Diagnos Inc
WealthAwesomeMarket cap
$57.49M
52W high
$0.52
52W low
$0.18
1W change
-5.00%
Beta
0.05
Analyst Price Targets
Based on analyst covering ADK
Wall Street analysts forecast ADK stock price to rise 215.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$1.50
+215.8% Upside
Current Price
C$0.47
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ADK's historical volatility
30-Day Vol
88.0%
Annualized
90-Day Vol
74.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.57
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.50 | C$0.37 โ C$0.68 |
| 60 trading days | C$0.54 | C$0.35 โ C$0.82 |
| 90 trading days | C$0.57 | C$0.34 โ C$0.96 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While Diagnos Inc has made strides in its product offerings, particularly with the CARA system, the recent price action suggests investors are cautious. The stock's performance metrics indicate potential volatility, which could affect short-term trading strategies.
Stock Performance Overview
Diagnos Inc's stock is currently trading at C$0.47, with a notable 52-week range of C$0.18 to C$0.52, indicating a significant potential for price fluctuations.
Bull case
The recent licensing of the CARA system in Saudi Arabia and Canada could open up new revenue opportunities for Diagnos Inc as demand for AI-assisted healthcare solutions increases. Analysts are optimistic, with an average target price significantly higher than the current trading price, suggesting potential for growth.
Bear case
Despite these positive developments, the stock has shown volatility. With a beta of 0.05, it indicates lower market risk but also limited growth potential. The recent weekly decline may reflect investor uncertainty, particularly in a sector sensitive to regulatory changes and market conditions.
Recent Stock Performance
Advertisement
Diagnos Inc's stock closed at C$0.47, reflecting no change over the last trading day. Over the past week, the stock has decreased by 5.00%, while it has gained 43.94% in the last month and 31.94% year-to-date. This performance indicates a volatile trading pattern, especially considering the stock's recent growth.
Company Developments
Recent headlines have highlighted Diagnos Inc's successful acquisition of medical device licenses for its CARA system in Canada and Saudi Arabia. These developments are significant as they allow the company to offer AI-assisted retinal image analysis, potentially expanding its market reach and driving future revenue growth.
Technical Picture
From a technical perspective, Diagnos Inc's stock is trading above its 50-day moving average of C$0.33 and its 200-day moving average of C$0.29, indicating a positive trend over the short and long term. The stock's 52-week range of C$0.18 to C$0.52 shows that it is currently trading at about 85% of its range. With a low beta of 0.05, the stock exhibits lower volatility relative to the market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
